Physician profile
Joseph Natole
NPI 1700842622
$16,107.66
in general payments reported to CMS, 2019-2025
62 companies · $4,654 in 2025
The $4,654 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,208 · 2020: $977 · 2021: $701 · 2022: $1,738 · 2023: $1,679 · 2024: $4,151 · 2025: $4,654.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $147.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,336.40 |
| Education | $146.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,086.81 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,671.63 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $1,473.99 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $1,315.25 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $725.81 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $704.10 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $601.47 | 2019-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $531.76 | 2019-2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $456.21 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $452.21 | 2023-2025 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $364.79 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $364.20 | 2019-2025 | Spravato |
| Abbott Laboratories | $357.67 | 2021-2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $304.04 | 2019-2025 | Veozah |
| Lundbeck LLC | $286.98 | 2020-2025 | Rexulti |
Show all 62 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $286.62 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Amgen INC. | $279.53 | 2019-2025 | Otezla, Repatha, Evenity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $275.87 | 2021-2023 | |
| Phathom Pharmaceuticals, INC. | $273.63 | 2023-2025 | Voquezna |
| Vanda Pharmaceuticals INC. | $249.69 | 2025 | Fanapt |
| Axsome Therapeutics, INC. | $244.39 | 2024-2025 | Auvelity, Symbravo, Sunosi |
| Harmony Biosciences LLC | $230.58 | 2022-2024 | |
| Exact Sciences Corporation | $219.67 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $191.51 | 2019-2024 | Verquvo, Capvaxive, Gardasil 9 |
| Verona Pharma, INC. | $150.03 | 2025 | Ohtuvayre |
| Sanofi-Aventis U.S. LLC | $144.47 | 2019-2023 | |
| Biohaven Pharmaceuticals, INC. | $125.57 | 2021 | |
| Jazz Pharmaceuticals INC. | $118.54 | 2019-2025 | |
| Paratek Pharmaceuticals, INC. | $96.93 | 2024-2025 | Nuzyra, Xhance |
| Supernus Pharmaceuticals, INC. | $94.47 | 2019-2020 | Xyosted |
| Teva Pharmaceuticals USA, INC. | $94.01 | 2019-2022 | |
| Ucb, INC. | $92.77 | 2024 | Nayzilam |
| Corcept Therapeutics | $91.18 | 2020-2024 | Korlym |
| Zyla Life Sciences, INC. | $79.67 | 2019-2020 | |
| Mylan Specialty L.P. | $76.24 | 2024 | Yupelri |
| Medtronic Minimed, INC. | $74.61 | 2019 | |
| Sunovion Pharmaceuticals INC. | $63.70 | 2022 | |
| Tolmar, INC. | $63.23 | 2024-2025 | Jatenzo |
| Kowa Pharmaceuticals America, INC. | $61.84 | 2024-2025 | Zoryve |
| Neurocrine Biosciences, INC. | $56.24 | 2019-2020 | |
| Alkermes, INC. | $49.87 | 2022-2023 | Aristada, Lybalvi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $49.67 | 2019-2025 | Xifaxan |
| Inspire Medical Systems, INC. | $49.14 | 2025 | Inspire |
| Verity Pharmaceuticals INC. | $48.53 | 2025 | Tlando |
| E.R. Squibb & Sons, L.L.C. | $46.46 | 2024-2025 | Eliquis |
| Biohaven Pharmaceutical Holding Company LTD. | $41.92 | 2022 | |
| Dexcom, INC. | $39.05 | 2022-2023 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $36.52 | 2024-2025 | Gvoke Hypopen |
| Collegium Pharmaceutical, INC. | $35.67 | 2025 | Xtampza, Belbuca |
| Takeda Pharmaceuticals U.S.A., INC. | $35.39 | 2025 | Trintellix |
| Mannkind Corporation | $34.86 | 2019-2022 | |
| Globus Medical, INC. | $27.79 | 2025 | Senza |
| Alnylam Pharmaceuticals INC. | $26.55 | 2024 | Onpattro |
| Boston Scientific Corporation | $24.03 | 2023 | Varithena Administration Pack |
| Ascendis Pharma Endocrinology INC | $21.43 | 2025 | Yorvipath |
| Viatris Specialty LLC | $19.09 | 2025 | Yupelri |
| Insulet Corporation | $17.14 | 2025 | Omnipod |
| Ibsa Pharma INC. | $16.39 | 2021 | |
| Corium, LLC | $16.33 | 2024 | Azstarys |
| Halozyme INC | $16.00 | 2023 | |
| Circassia INC. | $12.73 | 2019 | |
| Allergan, INC. | $11.19 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Natole listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.